title: Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury.
abstract: Synthetic surfactants allow examination of the effects of specific components of natural surfactant. To determine whether surfactant containing apoprotein C, dipalmitoyl-phosphatidylcholine, phosphatidylglycerol, and palmitic acid restores gas-exchanging function in acute lung injury (ALI), we administered such surfactant (in doses of 50 or 100 mg/kg and in volumes from 1 to 6 ml/kg) or phospholipid (PL) alone, by intratracheal instillation, to pigs with ALI induced by massive saline lavage. Animals ventilated with 100% O(2) and receiving 1, 2, 4, or 6 ml/kg of 50 mg/kg recombinant surfactant apoprotein C (rSP-C) surfactant or 2 ml/kg of 50 mg/kg PL (control) had mean arterial PO(2) values, 4 h after treatment, of 230, 332, 130, 142, or 86 Torr, respectively. Animals receiving 1, 2, or 4 ml/kg of 100 mg/kg rSP-C surfactant or 2 ml/kg of 100 mg/kg PL (control) had mean arterial PO(2) values of 197, 214, 148, or 88 Torr, respectively. Surfactant PL distribution was homogeneous. Hyaline membrane formation was reduced in treated animals. Thus, in this model of ALI, rSP-C with PL has the capacity to improve gas exchange and possibly modify lung injury.
authors.affiliation: Department of Medicine, University of California San Diego School of Medicine and San Diego Veterans Affairs HealthCare System, San Diego, California 92161, USA. rspragg@ucsd.edu
authors.forename: R G
authors.initials: RG
authors.lastname: Spragg
authors.forename: R M
authors.initials: RM
authors.lastname: Smith
authors.forename: K
authors.initials: K
authors.lastname: Harris
authors.forename: J
authors.initials: J
authors.lastname: Lewis
authors.forename: D
authors.initials: D
authors.lastname: Häfner
authors.forename: P
authors.initials: P
authors.lastname: Germann
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008170:Lung Compliance / Q000187:drug effects; D008171:Lung Diseases / Q000209:etiology / Q000517:prevention & control*; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D011175:Positive-Pressure Respiration; D011510:Proteolipids / Q000737:chemistry / Q000494:pharmacology*; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011663:Pulmonary Surfactants / Q000737:chemistry / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013500:Surface Tension; D013552:Swine; D007507:Therapeutic Irrigation / Q000009:adverse effects; D013997:Time Factors
chemical_list: D011510:Proteolipids; D011663:Pulmonary Surfactants; D011994:Recombinant Proteins; D010100:Oxygen